Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX shares the results of an analysis of venetoclax (Ven) and azacitidine (Aza) therapy in treatment-naïve FLT3-mutated acute myeloid leukemia (AML) patients who are unfit for intensive treatment. The median overall survival was 13.3 months for Ven+Aza, compared to 8.6 months for Aza patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.